BioCryst Pharmaceuticals, Inc. reported $941M of revenue over the trailing twelve months, +69% on the year before. 10 reported series are charted on this page, each one as filed. Revenue, trailing twelve months: $941M (to Q2 2026). Net income: −$385M, trailing twelve months to Q2 2026. Free cash flow: $373M, trailing twelve months to Q2 2026. Operating margin: −80%, trailing twelve months to Q2 2026.

BCRXBioCryst Pharmaceuticals, Inc.

Healthcare

$8.56+11% 1Y

$8.56

$6.2452 weeks$10.59

Latest close: back above its 200-day averageOct 9, 2026what changed →

BCRX as reported

BioCryst Pharmaceuticals, Inc. reported $941M of revenue over the trailing twelve months, +69% on the year before. 10 reported series are charted on this page, each one as filed.

$941M

Revenue, trailing twelve months · to Q2 2026 · +69% against the twelve months before

Net income: −$385M
Net income · +977% year on year · trailing twelve months to Q2 2026
Free cash flow: $373M
Free cash flow · +2269% year on year · trailing twelve months to Q2 2026
Operating margin: −80%
Operating margin · trailing twelve months to Q2 2026

Details›

Every series Ryufin has for BCRX, trailing twelve months
Series	Latest	Year on year	As of
Revenue	$941M	+69%	Q2 2026
Net income	−$385M	+977%	Q2 2026
EPS	−$1.49	+728%	Q2 2026
Gross margin	98%	n/a	Q2 2026
Operating margin	−80%	n/a	Q2 2026
Net margin	−89%	n/a	Q2 2026
ROE	−13%	n/a	Q2 2026
ROA	−30%	n/a	Q2 2026
ROIC	13%	n/a	Q2 2026
Free cash flow	$373M	+2269%	Q2 2026

Every figure straight from the statements filed with the SEC, no scoring. Per-share figures and share counts are restated for stock splits, so a split never shows up as a collapse. Open a series for its full history.